Table I.
Clinical and pathological characteristics of TCGA serous ovarian tumors from patients treated with standard platinum- and taxane-based chemotherapy.
| Characteristic | n | % |
|---|---|---|
| Age at diagnosis | ||
| <60 years | 148 | 56.06 |
| ≥60 years | 116 | 43.94 |
| Vital Status | ||
| Dead | 126 | 47.73 |
| Alive | 138 | 52.27 |
| Tumor grade | ||
| G2 | 21 | 7.95 |
| G3/G4 | 236 | 89.39 |
| Unknown | 7 | 2.65 |
| FIGO stage | ||
| IIIA/B | 21 | 7.95 |
| IIIC | 197 | 74.62 |
| IV | 46 | 17.42 |
| Lymph invasion | ||
| No | 38 | 14.39 |
| Yes | 63 | 23.86 |
| Unknown | 163 | 61.74 |
| Residual disease | ||
| ≤1 cm | 126 | 47.73 |
| >1 cm | 60 | 22.73 |
| Complete removal | 51 | 19.32 |
| Unknown | 27 | 10.23 |
| Clinical response to chemotherapy | ||
| Complete response | 155 | 58.71 |
| Partial response | 24 | 9.09 |
| Stable disease | 19 | 7.20 |
| Progressive disease | 12 | 4.55 |
| No data | 54 | 20.45 |
| Platinum status | ||
| Resistant | 49 | 20.25 |
| Sensitive | 112 | 46.28 |
| Too early | 34 | 14.05 |
| Unknown | 47 | 19.42 |
| p53 mutation type | ||
| LOF | 51 | 19.32 |
| Oncomorphic | 56 | 21.21 |
| Unclassified | 154 | 58.33 |
| WT | 2 | 0.76 |
| Unknown (no sequence information available) | 1 | 0.38 |
TCGA, The Cancer Genome Atlas; LOF, loss of function; WT, wild-type.